Development Command Under Contract No News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Cellphire Therapeutics Names Michael Gaffney as Company s New CEO News provided by Share this article Share this article ROCKVILLE, Md., April 20, 2021 /PRNewswire/  Cellphire Therapeutics, Inc., a biotechnology company developing next-generation platelet-based hemostatic therapeutics for application across multiple medical indications, announced today that Michael Gaffney has joined the company as Chief Executive Officer, effective immediately. Mr. Gaffney brings deep health sector insight, extensive operational experience, and proven strategy and capital markets expertise to Cellphire. He will also join the Company s board.  We re thrilled to have Mike join the Cellphire team, said Tom Dubin, Executive Chairman. He joins us at an exciting time, as Cellphire begins two Phase 2 clinical trials with two distinct investigational products, Thrombosomes® and Cryopreserved Platelets. Mike s proven and steady leadership and his background in health care and capital markets wil

Michael gaffneyTom dubinBiomedical advanced researchHuman servicesDevelopment command under contract noUs army medical researchDevelopment authorityDepartment of the armyBancroft groupCellphire therapeutics incUs navyDepartment of healthOffice of theOxford universityAs board of trusteesUnited states naval academy